Cofilin1及其Ser3位点磷酸化与老年非小细胞肺癌患者放疗敏感性的相关性研究
作者:
作者单位:

徐州市中心医院 放疗科,江苏 徐州,221000

作者简介:

胡翔,副主任医师,研究方向:肿瘤放射治疗。

通讯作者:

陈猛,硕士,副主任医师,研究方向:肿瘤学。

中图分类号:

R734.2

基金项目:


Correlation of cofilin1 and its phosphorylation at Ser3 with the radiotherapy sensitivity in elderly patients with non-small cell lung cancer
Author:
Affiliation:

Radiotherapy Department, Xuzhou Central Hospital, Xuzhou, Jiangsu, 221000, China

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 探讨Cofilin1及其Ser3位点磷酸化水平与老年非小细胞肺癌(NSCLC)患者放疗敏感性的相关性。方法 选取2013年6月—2015年4月于我院行手术切除、经病理确诊并接受术后放疗的老年NSCLC患者102例,根据疗效分为放疗敏感组(55例)和放疗抵抗组(47例),检测Cofilin1及其Ser3位点磷酸化蛋白Cofilin1(phospho S3)的表达,并记录患者的生存时间和生存率。结果 放疗抵抗组Cofilin1阳性表达组织的TNM分期和淋巴结转移率均显著升高,而Cofilin1(phospho S3)阳性表达组织显著降低(P<0.05)。放疗抵抗组的Cofilin1阳性表达率显著高于放疗敏感组,而放疗敏感组的Cofilin1(phospho S3)阳性表达率显著高于放疗抵抗组(P<0.05)。淋巴结转移、Cofilin1高表达、Cofilin1(phospho S3)低表达是放疗抵抗的独立预测因素(P<0.05)。放疗敏感组、Cofilin1阴性患者、Cofilin1(phospho S3)阳性患者的无进展生存时间(PFS)较长、5年生存率较高(P<0.05);放疗敏感组中,Cofilin1阴性和Cofilin1(phospho S3)阳性患者PFS最长、5年生存率最高(P<0.05);放疗抵抗组中,Cofilin1阳性和Cofilin1(phospho S3)阴性患者PFS最短、5年生存率最低(P<0.05)。结论 老年NSCLC患者的放疗敏感性与Cofilin1表达呈明显负相关,与Cofilin1的Ser3位点磷酸化水平呈显著正相关。Cofilin1及其Ser3位点磷酸化是放疗敏感性的独立预测因素,对老年NSCLC患者的预后评估具有重要意义。

    Abstract:

    Objective To investigate the correlation of cofilin1 and its phosphorylation at serine-3 (Ser3) with the radiotherapy sensitivity of elderly patients with non-small cell lung cancer (NSCLC).Methods A total of 102 elderly patients pathologically confirmed NSCLC, who were treated with surgical resection and postoperative radiotherapy in our hospital between June 2013 and April 2015, were selected in this study. According to their efficacy, patients were divided into radiotherapy-sensitive group (55 cases) and radiotherapy-resistant group (47 cases). The expression of cofilin1 and its Ser3-phosphorylated protein—cofilin1 (phospho S3) were detected. The survival time and survival rate of all patients were recorded.Results The radiotherapy-resistant group had higher TNM staging and rate of lymph node metastasis than the radiotherapy-sensitive group (P<0.05). The cofilin1-positive group also had higher TNM staging and lymph node metastasis rate than the cofilin1-negative group (P<0.05), while the cofilin1 (phospho S3)-positive group had lower TNM staging and lymph node metastasis rate than the cofilin1 (phospho S3)-negative group (P<0.05). The positive expression rate of cofilin1 was higher in the radiotherapy-resistant group than in the radiotherapy-sensitive group, and the positive expression rate of cofilin1 (phospho S3) was higher in the radiotherapy-sensitive group than in the radiotherapy-resistant group (P<0.05). Lymph node metastasis, high expression of cofilin1, and low expression of cofilin1 (phospho S3) were independent predictors of radiotherapy resistance (P<0.05). The progression-free survival (PFS) was longer and the 5-year survival rate was higher in the radiotherapy-sensitive group, cofilin1-negative group, and cofilin1 (phospho S3)-positive group (P<0.05). In the radiotherapy-sensitive group, patients with negative cofilin1 and positive cofilin1 (phospho S3) had the longest PFS and the highest 5-year survival rate (P<0.05). In the radiotherapy-resistant group, patients with positive cofilin1 and negative cofilin1 (phospho S3) had the shortest PFS and the lowest 5-year survival rate (P<0.05).Conclusion The radiotherapy sensitivity of elderly NSCLC patients is significantly negatively correlated with cofilin1 and positively correlated with the phosphorylation level at Ser3 of cofilin1. Cofilin1 and its phosphorylation at Ser3 are independent predictors of the sensitivity to radiotherapy, and they are of great significance in the prognosis assessment of elderly NSCLC patients.

    参考文献
    相似文献
    引证文献
引用本文

胡翔,陈猛,吴承骏,郝大为. Cofilin1及其Ser3位点磷酸化与老年非小细胞肺癌患者放疗敏感性的相关性研究[J].肿瘤药学,2022,(2):221-227 ( in Chinese)

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2020-05-22
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-05-16
  • 出版日期: 2022-04-28
我要投稿 杂志简介 杂志简介 二维码
TOP
×
《肿瘤药学》
《肿瘤药学》编辑部打假维权声明